Revenio Group Corporation, Stock Exchange Release, 27 February 2018 at 17.30
Revenio Group Corporation has published its Annual Report, Corporate Governance Statement and Remuneration Statement of 2017
Revenio has published its Annual Report 2017 in Finnish and English at:
http://reveniogroup.fi/fi/sijoittajille/tiedotteet-ja-julkaisut/taloudelliset-raportit/ (Finnish)
http://reveniogroup.fi/en/investors/releases-and-reports/financial-reports/ (English)
The Annual Report contains a business review, which provides information on Revenio's business and operating environment. It also includes the group Financial Statements of 2017, including a review by the Board and Auditor's note.
A Corporate Governance Statement has been published as part of the Annual Report 2017. In addition, a separate Remuneration Statement of 2017 has been published in Finnish and English.
The Annual Report including Financial Statements and the Corporate Governance Statement as well as the Remuneration Statement of 2017 are all available as an attachment to this Stock Exchange Release and in the web site http://www.reveniogroup.fi/en/investors/. Revenio does not publish the annual report in a printed format.
Attachments:
Annual Report 2017
Corporate Governance Statement 2017
Remuneration Statement 2017
REVENIO GROUP CORPORATION
For further information, please contact:
CEO and President Timo Hildén
tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2017, Revenio Group's net sales totaled EUR 26.8 million, with its operating margin, excluding non-recurring items, standing at 35.5 %. Revenio Group Corporation is listed on Nasdaq Helsinki.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/7d0f0620-d146-4a34-b263-86bdfdfd8d77
http://www.globenewswire.com/NewsRoom/AttachmentNg/f4a76a42-b85c-4eb4-8a59-3fa9cf36dbce
http://www.globenewswire.com/NewsRoom/AttachmentNg/ce15b11e-c450-4d6d-8bbb-9799bd304b77
